XGBoost identifies pathological microvascular invasion risk in liver cancer
Source check: Source checked. Not independent scientific confirmation.
Finding: An XGBoost model combined tumor diameter and three preoperative blood measures in 1,106 liver-cancer patients from two hospitals. Against postoperative pathology, AUC was 0.845 in 130 internal test patients and 0.793 in 451 patients from the second hospital. This retrospective classification does not establish improved surgical choices, survival benefit or a causal role of inflammation.
Technology: XGBoost; recursive feature elimination
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Boosted decision trees learn preoperative clinical associations with pathology-confirmed microvascular invasion.
- Test and result
- Training-cohort feature selection with internal and separate-hospital validation against pathological microvascular invasion.
- Limitation / still unknown
- Prospective clinical utility and treatment benefit remain unestablished; model selection compares multiple algorithms across validation cohorts and applicability beyond resected HCC is uncertain.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13525009/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Primary relevant model Methods, Results and limitations; exact primary identity and current primary PubMed correction/retraction relationships checked..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.